IGF-1 LR3 and IGF-1 DES are the two primary IGF-1 analogs used in research. Both overcome the IGFBP sequestration problem of native IGF-1 — but through different structural strategies, with distinct half-lives, receptor potencies, and research applications.
Why Native IGF-1 Is a Poor Research Tool
Insulin-like growth factor 1 (IGF-1) is a 70-amino acid polypeptide produced primarily in the liver under GH stimulation. It mediates GH’s anabolic effects via the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase activating PI3K-AKT-mTOR and RAS-MAPK signalling for cell growth, survival, and protein synthesis.
The fundamental challenge: native IGF-1 has a free half-life of only 12–15 minutes — rapidly bound by IGF-binding proteins (IGFBPs 1–6) and cleared. More than 99% of circulating IGF-1 is IGFBP-bound, dramatically reducing IGF-1R access. For research requiring sustained IGF-1R activation, native IGF-1 needs frequent re-dosing and its effect in serum is unpredictable. Both LR3 and DES were engineered to solve this problem.
IGF-1 LR3: The Long-Acting Systemic Analog
IGF-1 LR3 is an 83-amino acid recombinant analog produced by adding a 13-amino acid N-terminal extension to native IGF-1, with an arginine substitution at position 3 (replacing glutamic acid). Together these modifications reduce IGFBP binding affinity by approximately 1000-fold vs native IGF-1, while preserving IGF-1R binding — because the primary IGF-1R contact residues lie in the central and C-terminal domains, not the N-terminus that the extension sterically blocks for IGFBP interaction.
Half-life: 20–30 hours in vivo — making once-daily dosing sufficient for chronic rodent studies and maintaining effective IGF-1R stimulation throughout long cell culture incubation periods without medium replacement.
Best for: Sustained systemic IGF-1R activation; cell culture in serum-containing medium; chronic in vivo anabolic, anti-catabolic, or growth studies; any protocol where consistent IGF-1R occupancy over hours is required.
IGF-1 DES: The High-Potency Local Analog
IGF-1 DES (des(1-3)IGF-1) is a truncated form of native IGF-1 missing the first three N-terminal amino acids (Gly-Pro-Glu). This minimal 3-amino acid deletion reduces IGFBP binding affinity and simultaneously alters receptor binding orientation, producing approximately 10-fold higher potency at IGF-1R in cell-based assays vs native IGF-1 — making DES the most potent IGF-1 form per molecule at the receptor level.
Half-life: Shorter than LR3. DES lacks the N-terminal extension that provides LR3’s additional proteolytic resistance, so it is more rapidly degraded and cleared. For systemic in vivo applications, DES requires more frequent dosing.
Best for: Maximum IGF-1R potency in controlled short-duration windows; local tissue injection models (muscle, joint); serum-free or low-serum cell culture; dose-response studies where the 10× potency shift vs native IGF-1 is experimentally useful.
Direct Comparison
| Property | IGF-1 LR3 | IGF-1 DES | Native IGF-1 |
|---|---|---|---|
| Sequence length | 83 amino acids | 67 amino acids | 70 amino acids |
| Modification | 13-aa N-terminal extension + R3 substitution | N-terminal 3-aa deletion | — |
| IGFBP binding affinity | ~1000× lower than native | ~10× lower than native | High (99%+ bound in serum) |
| IGF-1R potency (in vitro) | Similar to native | ~10× higher than native | Reference standard |
| Half-life in vivo | 20–30 hours | Minutes–hours (context-dependent) | 12–15 min (free) |
| Dosing frequency (in vivo) | Once daily adequate | More frequent dosing required | Multiple doses/day required |
| MW / MS verification | ~9.1 kDa — critical to confirm | ~7.4 kDa | ~7.6 kDa |
| Primary application | Systemic sustained IGF-1R activation; chronic in vivo; serum cell culture | Local injection; high-potency short-duration; serum-free assays | When native sequence is specifically required |
Quality Verification for Recombinant Proteins
IGF-1 LR3 is an 83-amino acid recombinant protein (MW ~9.1 kDa) — not a short synthetic peptide. Analytical verification must include mass spectrometry to confirm correct molecular weight of the full-length protein. A high HPLC purity score on a truncated or misfolded protein would still show a clean chromatogram — only MS confirms the protein is complete and correctly assembled. QSC verifies IGF-1 LR3 by both HPLC (≥99% purity) and mass spectrometry (MW 9,117 Da confirmed), with Janoshik-independent COA on the product page.
GH–IGF-1 Axis Context
IGF-1 LR3 and DES are tools for direct IGF-1R activation, bypassing the GH–IGF-1 production axis. When the research question involves the intact axis — how GH secretion drives hepatic IGF-1 production, or how secretagogues affect the axis — researchers use GH secretagogues (sermorelin, CJC-1295, ipamorelin) or recombinant HGH rather than IGF-1 analogs. See: HGH vs GH Secretagogues Research Comparison.
Frequently Asked Questions
What is the difference between IGF-1 LR3 and IGF-1 DES?
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino acid recombinant analog with a 13-aa N-terminal extension and R3 arginine substitution, reducing IGFBP binding affinity ~1000-fold and extending half-life to 20–30 hours. IGF-1 DES (des(1-3)IGF-1) is a truncated 67-aa form missing the first 3 N-terminal amino acids, also reducing IGFBP binding and providing ~10× higher IGF-1R potency vs native IGF-1 — but with a shorter half-life than LR3. LR3 is preferred for sustained systemic IGF-1R activation; DES for high-potency short-duration or local tissue applications.
Which is more potent — IGF-1 LR3 or IGF-1 DES?
IGF-1 DES has approximately 10-fold higher potency at the IGF-1 receptor in cell-based assays compared to native IGF-1, and higher receptor binding affinity than LR3. However, IGF-1 LR3 has a much longer half-life (20–30 hours) due to its N-terminal extension. Potency in vivo depends on both receptor affinity and duration of exposure — for sustained systemic IGF-1R signalling, LR3 is generally preferred despite lower per-molecule potency.
What are IGF-binding proteins and why do they matter?
IGF-binding proteins (IGFBPs 1–6) sequester IGF-1 in circulation and extracellular fluid, greatly reducing IGF-1R access. More than 99% of circulating IGF-1 is IGFBP-bound. Both IGF-1 LR3 and DES were engineered to reduce IGFBP binding affinity, making them much more effective research tools for activating IGF-1R in serum-containing environments.
What is the IGF-1 receptor?
The IGF-1 receptor (IGF-1R) is a receptor tyrosine kinase structurally related to the insulin receptor, expressed on virtually all mammalian cell types. IGF-1R activation phosphorylates IRS-1/IRS-2 adaptor proteins, activating PI3K-AKT-mTOR and RAS-RAF-MAPK pathways — the primary cascades for cell growth, survival, protein synthesis, and glucose uptake.
What purity is QSC IGF-1 LR3?
QSC IGF-1 LR3 is verified at ≥99% purity by HPLC and mass spectrometry. MS verification of correct molecular weight (~9.1 kDa) is critical for confirming full-length protein integrity — a high purity score on a truncated protein would still show a clean HPLC chromatogram. Janoshik-independent COA is published on the product page.
IGF-1 LR3 · IGF-1 DES · HGH · Sermorelin · CJC-1295